RxDoctor Payments Data

Robert Hall, MD

Family Medicine · Moulton, ALNPI 1588724058

Payments from drug & device makers

$635in general payments, 2019–2025

Across 31 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$306
  • AbbVie$113
  • Amarin Pharma, Inc.$111
  • Novo Nordisk$47
  • AstraZeneca$27
  • Bioventus LLC$19
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$62498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC14$306
AbbVie(2 entities)7$113
Amarin Pharma, Inc.3$111
Novo Nordisk3$47
AstraZeneca2$27
Bioventus LLC1$19
Amgen1$14

How this compares

$635 in reported general payments places this provider in the 45th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$49,412
Medicare patients
182
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$60,257
TrulicityDulaglutide21$36,152
JardianceEmpagliflozin44$28,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,237
OzempicSemaglutide20$22,680
VraylarCariprazine Hcl14$19,462
LinzessLinaclotide28$17,858
XareltoRivaroxaban18$14,132
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$12,727
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,482
Tolterodine Tartrate ErTolterodine Tartrate57$5,623
Metoprolol Succinate424$5,602
Breo ElliptaFluticasone/Vilanterol13$5,034
Omeprazole396$4,903
Cyclobenzaprine Hcl87$4,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess$113$37,31942 claims
Lilly USA, LLCTrulicity$306$36,15221 claims
Novo NordiskOzempic$47$22,68020 claims
AstraZenecaBreztri Aerosphere$27$9,48215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Moulton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →